临床外科杂志 ›› 2026, Vol. 34 ›› Issue (3): 281-285.doi: 10.3969/j.issn.1005-6483.20241572

• 论著 • 上一篇    下一篇

血清单酰基甘油酯酶、甘油三磷酸脱氢酶1和人循环前胃泌素表达水平与乳腺癌病人分子分型及预后的关系

夏海水 房晓芳 王伟 马上   

  1. 061000 河北沧州,沧州市人民医院肿瘤内科(夏海水),内科(房晓芳),乳腺中心(王伟),甲状腺头颈外科(马上)
  • 收稿日期:2024-09-27 出版日期:2026-05-08 发布日期:2026-05-08
  • 通讯作者: 王伟,Email:gywaw6@163.com
  • 基金资助:
    河北省2024年度医学科学研究课题计划(20240644)

The relationship between the expression levels of serum MAGL,GPD1,hPG80 with the molecular typing and prognosis of breast cancer patients

XIA Haishui*,FANG Xiaofang,WANG Wei,MA Shang   

  1. *Department of Oncology,Cangzhou People's Hospital,Hebei,Cangzhou 061000,China
  • Received:2024-09-27 Online:2026-03-20 Published:2026-05-08

摘要: 目的 探讨乳腺癌病人血清单酰基甘油酯酶(MAGL)、甘油三磷酸脱氢酶1(GPD1)、人循环前胃泌素(hPG80)表达水平与分子分型及预后的关系。方法 2019年5月~2021年5月收治121例乳腺癌病人为癌症组,分子分型为Luminal A型62例,Luminal B型31例,HER2阳性型19例,三阴性乳腺癌9例。根据3年随访期间预后状况分为预后良好组82例,预后不良组39例。选取121例乳腺良性病变病人为良性病变组,另选择121例体检健康志愿者为对照组。采用酶联免疫吸附试验(ELISA)法对所有受试者血清样本MAGL、GPD1、hPG80表达水平进行检测;多因素Logistic回归分析乳腺癌病人预后不良影响因素;绘制受试者工作特征(ROC)曲线分析血清MAGL、GPD1、hPG80水平对乳腺癌病人预后不良的预测价值。结果 对照组MAGL为(10.74±2.35)μg/L,GPD1为(6.31±1.32)μg/L,hPG80为(2.41±0.56)pmol/L,癌症组分别为(5.93±1.12)μg/L、(4.07±0.81)μg/L和(5.34±1.25)pmol/L,良性病变组分别为(7.36±1.42)μg/L、(4.89±0.99)μg/L和(4.75±0.82)pmol/L,与对照组比较,癌症组和良性病变组病人血清hPG80表达水平上升,MAGL、GPD1表达水平下降,癌症组病人血清hPG80高于良性病变组,MAGL、GPD1低于良性病变组,差异有统计学意义(P<0.05)。不同分子分型乳腺癌病人Luminal A型血清MAGL为(6.34±1.15)μg/L,Luminal B型为(5.11±1.02)μg/L,HER2阳性型为(7.48±1.52)μg/L,三阴性乳腺癌为(2.62±0.72)μg/L,GPD1分别为(4.15±0.83)μg/L、(3.87±0.79)μg/L、(5.05±1.07)μg/L和(2.14±0.48)μg/L,hPG80分别为(5.03±1.10)pmol/L、(5.86±1.40)pmol/L、(4.65±1.32)pmol/L和(7.13±1.35)pmol/L,三阴性乳腺癌病人血清MAGL、GPD1表达水平最低,hPG80表达水平最高,差异有统计学意义(P<0.05);癌症组Ⅰ~Ⅱ期病人血清MAGL为(6.36±1.29)μg/L、Ⅲ~Ⅳ期为(5.64±1.06)μg/L;GPD1分别为(4.34±0.86)μg/L和(3.76±0.74)μg/L,MAGL和GPD1表达水平逐渐降低,差异有统计学意义(P<0.05);Ⅰ~Ⅱ期病人hPG80为(4.99±0.98)pmol/L,Ⅲ~Ⅳ期为(5.57±1.39)pmol/L,hPG80表达水平逐渐增加,差异有统计学意义(P<0.05);预后良好组MAGL为(6.52±1.23)μg/L,GPD1为(4.42±0.83)μg/L,hPG80为(4.96±1.05)pmol/L;预后不良组分别为(4.69±0.89)μg/L、(3.34±0.67)μg/L和(6.16±1.14)pmol/L,与预后良好组比较,预后不良组病人血清hPG80表达水平较高,MAGL、GPD1表达水平较低,差异有统计学意义(P<0.05);多因素Logistic回归分析结果表明,hPG80是影响乳腺癌病人预后不良的危险因素,MAGLR、GPD1是保护因素(P<0.05)。ROC曲线表明,血清MAGL、GPD1、hPG80水平联合预测乳腺癌病人预后不良的曲线下面积(AUC)值为0.911,大于MAGL和hPG80单独预测。结论 乳腺癌病人血清hPG80表达水平升高,MAGL、GPD1表达水平下降,三者水平与乳腺癌病人分子分型及预后有关。

关键词: 乳腺癌; 分子分型; 单酰基甘油酯酶; 甘油三磷酸脱氢酶1; 人循环前胃泌素; 预后

Abstract: Objective To investigate the relationship between the expression levels of serum monoacylglycerol esterase (MAGL),glycerol 3 phosphate dehydrogenase 1 (GPD1),human pre circulating gastrin (hPG80) and molecular typing and prognosis in breast cancer patients.Methods A total of 121 breast cancer patients from May 2019 to May 2021 were included as the cancer group.The molecular typing was Luminal A (62 cases),Luminal B (31 cases),HER2 positive (19 cases) and triple negative (9 cases) breast cancer.According to the prognosis,there were 82 cases in the good prognosis group and 39 cases in the poor prognosis group.121 patients with benign breast lesions were selected as the benign lesion group,and another 121 healthy volunteers who underwent physical examination were included as the control group.Enzyme linked immunosorbent assay (ELISA) was applied to detect the expression levels of MAGL,GPD1,and hPG80 in all personnel serum samples.Multivariate Logistic analysis was applied to analyze the adverse prognostic factors of breast cancer patients.ROC curve was drawn to analyze the predictive value of serum MAGL,GPD1,hPG80 levels for poor prognosis of breast cancer patients.Results Compared with the control group [MAGL=(10.74±2.35)μg/L,GPD1=(6.31±1.32)μg/L,hPG80=(2.41±0.56)pmol/L],the expression level of serum hPG80 in patients of the cancer group [MAGL=(5.93±1.12)μg/L,GPD1=(4.07±0.81)μg/L,hPG80=(5.34±1.25)pmol/L] and the benign lesion group [MAGL=(7.36±1.42)μg/L,GPD1=(4.89±0.99)μg/L,hPG80=(4.75±0.82)pmol/L] increased,while the expression levels of MAGL and GPD1 decreased. The serum hPG80 in the cancer group was higher than that in the benign lesion group, while MAGL and GPD1 were lower than those in the benign lesion group, and the differences were statistically significant (P < 0.05).Serum MAGL in different molecular subtypes of breast cancer patients [Luminal A=(6.34±1.15)μg/L,Luminal B=(5.11±1.02)μg/L,HER2 positive=(7.48±1.52)μg/L,Triple negative breast cancer=(2.62±0.72)μg/L],GPD1[Luminal A=(4.15±0.83)μg/L,Luminal B=(3.87±0.79)μg/L,HER2 positive=(5.05±1.07)μg/L,Triple negative breast cancer=(2.14±0.48)μg/L],hPG80[Luminal A=(5.03±1.10)pmol/L,Luminal B=(5.86±1.40)pmol/L,HER2 positive=(4.65±1.32)pmol/L,Triple negative breast cancer=(7.13±1.35)pmol/L] showed different expression levels.The expression levels of serum MAGL and GPD1 in triple negative breast cancer patients were the lowest,and the expression level of hPG80 was the highest(P<0.05).With the increase of TNM stage,the serum levels of MAGL[Ⅰ-Ⅱ stage=(6.36±1.29)μg/L,Ⅲ-Ⅳ stage=(5.64±1.06)μg/L] and GPD1[Ⅰ-Ⅱ stage=(4.34±0.86)μg/L,Ⅲ-Ⅳ stage =(3.76±0.74)μg/L] in the cancer group gradually decreased,and the level of hPG80[Ⅰ-Ⅱ stage=(4.99±0.98)pmol/L,Ⅲ-Ⅳ stage =(5.57±1.39)pmol/L] gradually increased(P<0.05).Compared with the good prognosis group[MAGL=(6.52±1.23)μg/L,GPD1=(4.42±0.83)μg/L,hPG80=(4.96±1.05)pmol/L],the expression level of serum hPG80 in the poor prognosis[MAGL=(4.69±0.89)μg/L,GPD1=(3.34±0.67)μg/L,hPG80=(6.16±1.14)pmol/L] group was higher,and the expression levels of MAGL and GPD1 were lower(P<0.05).Multivariate Logistic analysis showed that hPG80 was a risk factor for poor prognosis of breast cancer patients,MAGL and GPD1 were protective factors(P<0.05).ROC curve revealed that the area under the curve (AUC) value of serum MAGL,GPD1 and hPG80 levels for predicting poor prognosis of breast cancer patients was 0.911,obviously higher than that of MAGL,GPD1 and hPG80 alone.Conclusion The expression level of serum hPG80 in breast cancer patients increases,while the expression level of MAGL and GPD1 decrease.The three levels are related to the molecular typing and prognosis of breast cancer patients.

Key words: breast cancer; molecular typing; monoacylglycerol esterase; glycerol 3 phosphate dehydrogenase 1; human pre circulating gastrin; prognosis

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 黄洪锋. 关注公民逝世后器官捐献肾移植受体围手术期感染的预防与处理[J]. 临床外科杂志, 2016, 24(10): 732 .
[2] 胡善彪;余少杰;彭龙开. 婴幼儿供肾移植[J]. 临床外科杂志, 2016, 24(10): 741 .
[3] 杨华;李新长;龙成美;等. 公民逝世后器官捐献供肾移植临床分析[J]. 临床外科杂志, 2016, 24(10): 747 .
[4] 陈忠;王耀东;田毅峰;等. 肝胆管结石病规范化治疗的临床分析[J]. 临床外科杂志, 2016, 24(10): 753 .
[5] 江帆;孙权;吴国俊;等. 不同引流方式对恶性梗阻性黄疸患者细胞免疫的影响[J]. 临床外科杂志, 2016, 24(10): 760 .
[6] 阿布力克木·毛拉尤甫;郑秉礼. 胰腺实性假乳头状瘤45例手术治疗分析[J]. 临床外科杂志, 2016, 24(10): 764 .
[7] 贺长林;黎秋曦;刘锋;等. 腹腔镜阑尾切除术中转开腹及再手术的处理体会[J]. 临床外科杂志, 2016, 24(10): 802 .
[8] 涂儒鸿;黄昌明. 腹腔镜胃癌根治术淋巴结清扫技巧[J]. 临床外科杂志, 2016, 24(11): 809 .
[9] 周振宇;汪路明;王一青;等. 肺部多发结节468例诊疗分析[J]. 临床外科杂志, 2016, 24(11): 865 .
[10] 严文波;潘伟华;武志祥;等. 新生儿先天性腹裂外科处理后转归[J]. 临床外科杂志, 2016, 24(11): 879 .